After its third strong quarter in a row, Nippon Chemiphar Co., Ltd. has revised upwards its forecasts for its FY2021 financial year ending 31 March 2022, anticipating an extra ¥1bn ($8.7m) in sales and an extra ¥250m in operating income.
Chemiphar Revises Forecasts Up Following Q3 Performance
Japanese Generics Firm Finally Shaking Off Impact Of NHI Revision And COVID-19
Three strong quarters in a row have prompted Nippon Chemiphar to revise up its FY2021 forecasts, thanks to strong sales of generic drugs launched in FY2020 and June 2021, as well as an increase in demand due to quality control issues faced by competitors.
